By Professor John Philip Chalmers

Preprints

Chen C; Ouyang M; Ong S; Zhang L; Zhang G; Delcourt C; Mair G; Liu L; Billot L; Li Q; Chen X; Parsons M; Broderick J; Demchuk A; Bath P; Donnan G; Levi C; Chalmers J; Lindley R; Martins S; Pontes-Neto O; Venturelli PM; Olavarría V; Lavados P; Robinson T; Wardlaw J; Li G; Wang X; Song L; Anderson C; Investigators ENCHANTED, 2023, Effects of Intensive Blood Pressure Lowering on Cerebral Ischaemia in Thrombolysed Patients: Insights from the Enchanted Trial, http://dx.doi.org/10.2139/ssrn.4314023

Neuen B; Jun M; Wick J; Kotwal S; Badve S; Jardine M; Gallagher M; Chalmers J; Nallaiah K; Perkovic V; Peiris D; Rodgers A; Woodward M; Ronksley P, 2023, Estimating the population-level kidney benefits of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease in Australian primary care, http://dx.doi.org/10.1101/2023.06.26.23291881

Jun M; Wick J; Neuen B; Kotwal S; Badve S; Woodward M; Chalmers J; Peiris D; Rodgers A; Nallaiah K; Jardine M; Perkovic V; Gallagher M; Ronksley P, 2023, The prevalence of chronic kidney disease in Australian primary care: analysis of a national general practice dataset, http://dx.doi.org/10.1101/2023.06.18.23290762

Back to profile page